Media coverage about Irhythm Technologies (NASDAQ:IRTC) has trended somewhat positive on Monday, according to Accern Sentiment. The research firm identifies negative and positive news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Irhythm Technologies earned a news impact score of 0.12 on Accern’s scale. Accern also assigned media stories about the company an impact score of 44.8232450884977 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the news articles that may have effected Accern’s analysis:
- Irhythm Technologies (IRTC) Upgraded by Zacks Investment Research to Hold (americanbankingnews.com)
- Irhythm Technologies (IRTC) Downgraded to Sell at Zacks Investment Research (americanbankingnews.com)
- Irhythm Technologies (IRTC) and Its Rivals Head to Head Analysis (americanbankingnews.com)
- iRhythm Technologies Appoints UCLA and Cedars-Sinai Professor C. Noel Bairey Merz, M.D. to its Board of Directors (finance.yahoo.com)
- Comparing T2 Biosystems (TTOO) & Irhythm Technologies (IRTC) (americanbankingnews.com)
A number of analysts recently issued reports on the company. BidaskClub downgraded Irhythm Technologies from a “buy” rating to a “hold” rating in a research report on Friday, March 16th. Northland Securities reissued a “hold” rating and set a $60.00 price target on shares of Irhythm Technologies in a research report on Wednesday, March 14th. BMO Capital Markets began coverage on Irhythm Technologies in a research report on Monday, March 5th. They set an “outperform” rating and a $76.00 price target on the stock. JPMorgan Chase boosted their price target on Irhythm Technologies from $62.00 to $67.00 and gave the stock an “overweight” rating in a research report on Thursday, February 15th. Finally, ValuEngine raised Irhythm Technologies from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $69.29.
Irhythm Technologies (NASDAQ:IRTC) last announced its quarterly earnings results on Wednesday, February 14th. The company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.13). The business had revenue of $28.20 million for the quarter, compared to analyst estimates of $26.79 million. Irhythm Technologies had a negative return on equity of 34.44% and a negative net margin of 29.87%. Irhythm Technologies’s quarterly revenue was up 50.8% compared to the same quarter last year. During the same period last year, the firm earned ($0.37) EPS. analysts anticipate that Irhythm Technologies will post -1.54 earnings per share for the current fiscal year.
In other news, Director Vijay K. Lathi sold 169,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 21st. The stock was sold at an average price of $62.41, for a total value of $10,547,290.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Kevin M. King sold 60,000 shares of the company’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $64.52, for a total value of $3,871,200.00. Following the completion of the transaction, the insider now directly owns 201,842 shares in the company, valued at approximately $13,022,845.84. The disclosure for this sale can be found here. In the last three months, insiders have sold 352,452 shares of company stock worth $22,613,610. Company insiders own 23.30% of the company’s stock.
About Irhythm Technologies
iRhythm Technologies, Inc, a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. The company offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias.
Receive News & Ratings for Irhythm Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Irhythm Technologies and related companies with MarketBeat.com's FREE daily email newsletter.